NEWS
View news from our Featured Companies.
Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
Encinitas, California--(August 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal,...
NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome
CARMEL, Ind., Aug. 22, 2023 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two...
Zoomd to Report Second Quarter 2023 Financial Results on August 29, 2023
Conference call to be conducted on August 29, 2023, at 11 a.m. ET. VANCOUVER, British Columbia, Aug. 22, 2023 /CNW/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing...
Mogo Launches Normal Course Issuer Bid on TSX
VANCOUVER, British Columbia - Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) ("Mogo" or the "Company") today announced that, in addition to the Company's existing common share buyback program launched on the NASDAQ in March 2022 (the "NASDAQ Bid"), the Company has received...
NeurAxis Announces Over $8 Million in IB-Stim™ Revenue
CARMEL, Ind., Aug. 17, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced it has...
ARIANNE PHOSPHATE ADDS MARK EDINGER AS AN ADVISOR
-former senior executive of Nutrien Ltd. phosphate division to enhance business advisory team DAN: TSX-V (Canada)JE9N: FSE (Germany)DRRSF: OTCQX (USA) SAGUENAY, QC, Aug. 17, 2023 /CNW/ - Arianne Phosphate (the "Company" or "Arianne") (TSXV: DAN) (OTCQX: DRRSF)...
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
- 402 patients completed enrollment across multiple sites in the US, Europe, and Asia - - Topline data for Phase 3 RECOVER study expected in October 2023 - - Completion of 1-year open-label extension clinical study expected in Q3 2024 - CUPERTINO, Calif., Aug. 17,...
Modular Medical Partners with Phillips-Medisize to Expand Insulin Delivery Alternatives
SAN DIEGO, CA / August 16, 2023 / Modular Medical, Inc. (Nasdaq:MODD), a development stage insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced a collaboration under which...
Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
Encinitas, California--(August 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference. As part of the talk, Kiora President & CEO Brian...
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update
ROCKVILLE, Md., Aug. 15, 2023 -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate...
NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023
CARMEL, Ind., Aug. 15, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced a poster...
Scientific Industries Reports Financial Results for Second Quarter 2023
Benchtop Lab Equipment Revenue Up Led by Torbal Division's 48% Increase - Bioprocessing Revenue Up 41%BOHEMIA, NY / August 14, 2023 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider and a developer of digitally simplified bioprocessing...
Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- Topline data for global pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected in October 2023 - - Completion of 1-year open-label extension clinical trial for brilaroxazine in schizophrenia expected in Q3 2024 - CUPERTINO, Calif., Aug. 14, 2023...
Scientific Industries to Report Second Quarter 2023 Financial Results on August 14, 2023
Investor Call to be held Tuesday, August 15th at 11:00 AM Eastern TimeBOHEMIA, NY / August 11, 2023 / Scientific Industries, Inc. (OTCQB:SCND), a life sciences tool provider, and a developer of digitally simplified bioprocessing products, announced today it will file...
Mogo Extends Innovative Marketing Agreement with Postmedia to End of 2024
VANCOUVER, British Columbia - Mogo Inc. (TSX:MOGO) (NASDAQ:MOGO) ("Mogo" or the "Company"), a digital payments and financial technology company, today announced that it has amended its marketing collaboration agreement with Postmedia Network Inc. ("Postmedia") and...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
PORTLAND, Maine, Aug. 10, 2023 -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy...
SenesTech Announces Second Quarter 2023 Financial Results
July 2023 Sales Increased 126% as New Initiatives Take Hold Expanded Product Offerings Expected to Drive Future Growth PHOENIX, Aug. 10, 2023 -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and...
Mogo Reports Results for Q2 2023 and Share Consolidation
Gross Profit of $11.9 million, up 4.9% yr/yr Adjusted EBITDA of $1.8 million in the quarter, up from ($4.1) million in Q2 2022 Company increases full-year Adjusted EBITDA guidance to $7.0 million to $9.0 million Subsequent to quarter end received ~87 million shares in...
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PONTE VEDRA, Fla., Aug. 10, 2023 -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in...
NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin
CARMEL, Ind., Aug. 10, 2023 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlighted...
LiqTech International Announces Second Quarter 2023 Financial Results
BALLERUP, Denmark, Aug. 10, 2023 -- LiqTech International, Inc. (NASDAQ: LIQT) ("LiqTech"), a clean technology company that manufactures and markets highly specialized filtration technologies, today announced its financial results for the second quarter of 2023 for...
Modular Medical to Present at the Sidoti Micro-Cap Virtual Conference on August 17
SAN DIEGO, CA / August 10, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (Nasdaq:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today...
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
Strong quarter with total net sales of $20.3 million, a gross margin of 60.8% and a net loss of $2.2 million while achieving a positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the three months ended June 30, 2023. LOS ANGELES - ChromaDex...
NeurAxis Announces Pricing of Initial Public Offering
CARMEL, Ind., Aug. 09, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and...